NCT01315041

Brief Summary

Hot flushes are common symptoms in women after menopause, and are important causes of discomfort and lead to high number of medical consultations. Hormone replacement therapy is an effective treatment, however it can bring undesirable consequences and may be contraindicated for some women. Options are inhibitors of serotonin or serotonin-norepinephrine reuptake, gabapentin, herbal medicines and homeopathy. None of these therapies is widely accepted of effective. Therefore, the search for new therapeutic options is highly desirable. Ingestion of malagueta pepper fruits (Capsicum frutescens L. var. malagueta) causes sensations similar to those experienced by menopausal women during hot flushes. By the principle of homeopathy, "the like cures the like", the objectives of this study are: (a) to determinate whether pathogenesis of a homeopathic medicine made from C. frutescens fruits include symptoms like hot flushes, and (b) whether this medicine is effective on hot flushes relief in women after menopause. There will be 2 distinct phases. Phase 1 is the determination of the medicine's pathogenesis in healthy volunteers, in a randomized placebo-controlled, double-blind design. Phase 2 is the investigation of the medicine's effects on hot flushes of women after menopause, in a randomized placebo-controlled, double-blind design. The investigators expect a significant reduction on symptoms perception, assessed by internationally validated tools. The study is expected to last for 18 months, with 36 patients included in each phase.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Dec 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 14, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 15, 2011

Completed
3.7 years until next milestone

Study Start

First participant enrolled

December 1, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

January 27, 2016

Status Verified

January 1, 2016

Enrollment Period

1 year

First QC Date

March 14, 2011

Last Update Submit

January 26, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • MYMOP (Measure Yourself Medical Outcome Profile)

    4 and 16 weeks

  • ORIDL (Outcome Related to Impact on Daily Living)

    4 and 16 weeks

Study Arms (2)

"Pi" medicine

ACTIVE COMPARATOR
Drug: Capsicum frutescens fruits, homeopathic medicine

Placebo

PLACEBO COMPARATOR
Drug: Inert alcoholic solution

Interventions

5 drops, PO, 3 times a day, during 16 weeks

"Pi" medicine

5 drops, PO, 3 times a day, during 16 weeks

Placebo

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Phase 1: healthy volunteers
  • Phase 2: menopaused women with hot flushes

You may not qualify if:

  • Illiteracy;
  • Have been enrolled in another clinical trial within the last 6 months;
  • Use of pharmacological therapies for hot flushes;
  • Have any degree of vulnerability;
  • Allergy or hypersensitivity to Capsicum species;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Casa Espirita Terra de Ismael

Jardinópolis, São Paulo, 14680-000, Brazil

Location

MeSH Terms

Interventions

Homeopathy

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeutics

Study Officials

  • Fabio Carmona, MD, PhD

    University of Sao Paulo

    STUDY DIRECTOR
  • Mateus A Angelucci, MD, MSc

    University of Sao Paulo

    PRINCIPAL INVESTIGATOR
  • Ana MS Pereira, PhD

    University of Ribeirao Preto

    STUDY CHAIR
  • Edson Z Martinez, PhD

    University of Sao Paulo

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 14, 2011

First Posted

March 15, 2011

Study Start

December 1, 2014

Primary Completion

December 1, 2015

Study Completion

January 1, 2016

Last Updated

January 27, 2016

Record last verified: 2016-01

Locations